Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
![](/46/pdcnewsitem/11/86/39/CPHI%20online%20images%20(4).png)
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity.
Researchers at Flinders University, Adelaide, Australia, have demonstrated a potential molecular link between COVID-19 and serotonin cells in the gut, suggesting that gut health may have a role to play in driving COVID-19 infection.
The collaborative study investigated gene expression amongst various different cell types lining the gut wall, sequencing and analysing whole genomes from thousands of individuals cells within the intestine. Specialised cells in the gut that synthesised and released serotonin were also discovered to possess a highly enriched expression of a specific SARS-CoV-2 receptor, and were the only type of cells to express all genes associated with COVID-19.
The research may provide further insight into what drives COVID-19 infection and disease severity, potentially supporting previous evidence suggesting antidepressants known as selective serotonin reuptake inhibitors could reduce the severity of COVID-19 symptoms after infection.
Damien Keating, professor and Deputy Director of the Flinders Health and Medical Research Institute and Head of the Gut Sensory Systems research group, commented: “Our study endeavoured to understand whether the gut could be a site of disease transmission and what genes might be associated with the virus entering the cells lining the gut wall.” As the exact site of infection and primary drivers of COVID-19 severity are yet to be fully understood, the researchers behind this study hope to provide important information on the gut’s role in the virus. “Our study adds further evidence that COVID-19 is far more likely to infect cells in the gut and increase serotonin levels through direct effects on the specific gut cells, potentially worsening disease outcomes,” added Keating. “As COVID-19 continues to circulate, further research will be required to advance our understanding of the gut’s role in the virus and continue to find treatment options to work alongside vaccinations.”
The study was published in leading gastrointestinal research journal Gut.
Want to know more about the gut and how it affects overall health? Read our Consumer health trends webinar roundup on the gut microbiome, or watch the webinar itself on-demand.
Source: How the gut may help to drive COVID-19 – News (flinders.edu.au)
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance